SMi’s Ophthalmic Drugs: Queen's University Belfast and Santen to Present

Opening Keynote

Hear from Queen's University Belfast and Santen as they present the opening addresses in London
on 26 – 27 November 2018.

London, United Kingdom, November 08, 2018 --(PR.com)-- Day 1 - Opening Keynote Address: New
Strategies for Treating Retinal Vascular Diseases

Retinal vascular diseases are a leading cause of blindness in the Western world. Advancement in the
clinical management of these diseases has been fast-paced, with new treatments becoming available as
well as license extensions of existing treatments.*

Discover advancements in the treatment of ocular diseases as Professor Alan Stitt, Dean of Innovation
and Impact, Queen's University Belfast presents an overview of pathogenesis of ischaemic retinopathies,
a disease that affects the immature retinal vascular system, as well as the cellular and molecular
mechanisms of the disease.

Day 2 - Opening Keynote Address: Glaucoma / retinal protection treatments

Glaucoma is an optic neuropathy, specifically a neurodegenerative disease characterised by loss of retinal

ganglion cells (RGCs) and their axons. The pathogenesis of RGC loss in glaucoma remains incompletely
understood and a broad range of possible mechanisms have been implicated.*

Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen, USA will
present the latest developments in the treatment of glaucoma, which will explore the novel and recently
approved drugs in view, new devices to lower and control IOP and a case for pathways to
retinoprotection.

SMi Presents the 2nd annual:

Ophthalmic Drugs 2018
Date: 26th - 27th November 2018
Workshops: 28th November 2018
Location: Copthorne Tara Hotel, London UK
Website: www.ophthalmicdrugs.com

Sponsors: AERO PUMP | Experimentica | Nemera | Ora Europe Ltd

Sources: https://bit.ly/2BVa7lS | https://go.nature.com/2PEYouy

Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
SMi Group
Neill Howard
207-827-6164
Contact via Email
http://www.social-media-pharma.com

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/769396

Page 2/2
PR.com Press Release Distribution Terms of Use